Shire, Teva settle litigation over ADHD drug

PHILADELPHIA British drug maker Shire and generic drug maker Teva Pharmaceuticals have settled litigation over an authorized generic version of an attention deficit hyperactivity disorder drug, Shire announced Wednesday.

Shire has supplied Teva with an authorized generic of Adderall XR (amphetamine and dextroamphetamine) since April, but Drug Enforcement Administration restrictions had limited Shire’s ability to supply the drug due to its containing amphetamine, a controlled substance.

Teva had filed a lawsuit against Shire, claiming it was in breach of contract, but the DEA expanded Shire’s quota of the drug for 2009 so that it could supply more of it to Teva. In response, Teva has dismissed the lawsuit.